230 related articles for article (PubMed ID: 21694634)
1. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
Park KT; Perez F; Tsai R; Honkanen A; Bass D; Garber A
J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):489-96. PubMed ID: 21694634
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis.
Park KT; Tsai R; Perez F; Cipriano LE; Bass D; Garber AM
Ann Surg; 2012 Jul; 256(1):117-24. PubMed ID: 22270693
[TBL] [Abstract][Full Text] [Related]
3. Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis.
Taleban S; Van Oijen MG; Vasiliauskas EA; Fleshner PR; Shen B; Ippoliti AF; Targan SR; Melmed GY
Dig Dis Sci; 2016 Feb; 61(2):550-9. PubMed ID: 26434930
[TBL] [Abstract][Full Text] [Related]
4. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
5. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
Tappenden P; Ren S; Archer R; Harvey R; James MM; Basarir H; Stevens J; Lobo A; Hoque S
Pharmacoeconomics; 2016 Oct; 34(10):1023-38. PubMed ID: 27125898
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
Yen EF; Kane SV; Ladabaum U
Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
Punekar YS; Hawkins N
Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
Doherty GA; Miksad RA; Cheifetz AS; Moss AC
Inflamm Bowel Dis; 2012 Sep; 18(9):1608-16. PubMed ID: 21905173
[TBL] [Abstract][Full Text] [Related]
10. On the cost-effectiveness of the use of probiotics in inflammatory bowel disease.
Samnaliev M; Lightdale JR
J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):473. PubMed ID: 21768884
[No Abstract] [Full Text] [Related]
11. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis.
Ung V; Thanh NX; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Fedorak RN
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1871-8.e8. PubMed ID: 24674943
[TBL] [Abstract][Full Text] [Related]
12. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
14. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
16. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
Mahmoud R; van Lieshout C; Frederix GWJ; Jharap B; Oldenburg B
J Crohns Colitis; 2021 May; 15(5):709-718. PubMed ID: 33125060
[TBL] [Abstract][Full Text] [Related]
17. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
Saini SD; Waljee AK; Higgins PD
Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1143-51. PubMed ID: 22610010
[TBL] [Abstract][Full Text] [Related]
18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
19. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
